InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting
April 20 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that the company will be giving two oral presentations at
the 2017 American Spinal Injury Association (ASIA) Annual
Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New
Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and
Scientific Support, will present a clinical trial update during the
“Clinical Trials 360-degree” session sponsored by Spinal Cord
Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr.
Aimetti will also present an abstract entitled "Relationship of
ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization
Costs in Thoracic Spinal Cord Injury" during a general session on
Saturday, April 29. The abstract is co-authored by Dr. Aimetti,
Ellen Dukes, Ph.D., Steven Kirshblum, M.D., Sarah Qin, M.B.A.,
Rebecca Bornheimer, B.A., and Gerry Oster, Ph.D. In addition to the
two oral presentations, the company will have an exhibit booth at
the meeting.
Mark Perrin, Chairman and CEO, said, “The American Spinal Injury
Association Annual Scientific Meeting will allow us to continue to
strengthen and expand our relationships within the spinal cord
injury research and care network, and we look forward to having a
significant presence at this meeting. We are also pleased to be
providing an update on our clinical program, especially given our
significant progress throughout the start of this year.”
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in The INSPIRE Study for the
treatment of patients with acute, complete (AIS A), thoracic
traumatic spinal cord injury and a pilot study for acute, complete
(AIS A), cervical (C5-T1) traumatic spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as "believe," "anticipate,"
"intend," "estimate," "will," "may," "should," "expect," “designed
to,” “potentially,” and similar expressions, and include statements
regarding the safety and effectiveness of the Neuro-Spinal Scaffold
and the progress of the clinical program. Any forward-looking
statements contained herein are based on current expectations, and
are subject to a number of risks and uncertainties. Factors that
could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the company’s ability to successfully
open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the company’s ability to commercialize its products; the
company’s ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the company’s
products and technology in connection with the treatment of spinal
cord injuries; the availability of substantial additional funding
for the company to continue its operations and to conduct research
and development, clinical studies and future product
commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval,
marketing and distribution plans and strategies identified and
described in more detail in the company’s Annual Report on Form
10-K for the year ended December 31, 2016, and its other filings
with the SEC, including the company’s Form 10-Qs and current
reports on Form 8-K. The company does not undertake to update these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170420005276/en/
InVivo Therapeutics Holdings Corp.Heather Hamel,
617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024